鉴定RBM12为胎儿血红蛋白表达的新型调控因子
胎儿至成人血红蛋白转换具有临床意义,因重新激活胎儿血红蛋白(HbF)可显著降低镰状细胞病(SCD)和β-地中海贫血的发病率和死亡率。本研究通过靶向含RNA甲基转移酶和/或RNA识别基序(RRM)结构域的RNA结合蛋白(RBP)进行CRISPR/Cas9筛选,鉴定出RNA结合基序蛋白12(RBM12)为新型HbF抑制因子;RBM12缺失可诱导HbF表达并减轻SCD患者红系细胞的镰状化,且对细胞成熟负面影响极小。
要点
- CRISPR/Cas9筛选鉴定RBM12为新型HbF抑制因子
- RBM12缺失诱导HbF表达并减轻SCD患者红系细胞镰状化,对细胞成熟负面影响极小
- RBM12功能独立于已知主要HbF调控因子,优先结合转录本5'非翻译区
核心结论
- RBM12是HbF的负调控因子,揭示了胎儿至成人血红蛋白转换的额外调控层,并拓宽了SCD和β-地中海贫血的潜在治疗靶点池。
研究设计与样本
- 研究采用基于CRISPR/Cas9的筛选,靶向含RNA甲基转移酶和/或RNA识别基序(RRM)结构域的RNA结合蛋白(RBP)。
主要发现
- RBM12缺失诱导HbF表达并减轻SCD患者红系细胞的镰状化,对细胞成熟负面影响极小。
- 转录组和蛋白质组分析显示RBM12功能独立于已知主要HbF调控因子。
- 增强型交联免疫沉淀结合高通量测序显示RBM12强烈优先结合转录本的5'非翻译区。
- RBM12的5个RRM结构域中第一个为必需,与连接域一起足以介导RBM12调控HbF。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The fetal-to-adult hemoglobin transition is clinically relevant because reactivation of fetal hemoglobin (HbF) significantly reduces morbidity and mortality associated with sickle cell disease (SCD) and β-thalassemia. Most studies on the developmental regulation of the globin genes, including genome-wide genetics screens, have focused on DNA binding proteins, including BCL11A and ZBTB7A/LRF and their cofactors. Our understanding of RNA binding proteins (RBPs) in this process is much more limited. Two RBPs, LIN28B and IGF2BP1, are known posttranscriptional regulators of HbF production, but a global view of RBPs is still lacking. Here, we carried out a CRISPR/Cas9-based screen targeting RBPs harboring RNA methyltransferase and/or RNA recognition motif (RRM) domains and identified RNA binding motif 12 (RBM12) as a novel HbF suppressor. Depletion of RBM12 induced HbF expression and attenuated cell sickling in erythroid cells derived from patients with SCD with minimal detrimental effects on cell maturation. Transcriptome and proteome profiling revealed that RBM12 functions independently of major known HbF regulators. Enhanced cross-linking and immunoprecipitation followed by high-throughput sequencing revealed strong preferential binding of RBM12 to 5' untranslated regions of transcripts, narrowing down the mechanism of RBM12 action. Notably, we pinpointed the first of 5 RRM domains as essential, and, in conjunction with a linker domain, sufficient for RBM12-mediated HbF regulation. Our characterization of RBM12 as a negative regulator of HbF points to an additional regulatory layer of the fetal-to-adult hemoglobin switch and broadens the pool of potential therapeutic targets for SCD and β-thalassemia.
引用
- Wakabayashi A, Kihiu M, Sharma M, et al. Identification and characterization of RBM12 as a novel regulator of fetal hemoglobin expression. Blood Adv. 2022. PMID: 35622975. doi:10.1182/bloodadvances.2022007904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。